Please login to the form below

Not currently logged in

UCB submits brivaracetam for use in epilepsy

Files drug in both the US and EU

Belgian pharma company UCB has filed its investigational drug brivaracetam for approval to treat epilepsy in both the US and EU.

Both the US FDA and the European Medicines Agency (EMA) have accepted brivaracetam for review as an adjunctive therapy for the treatment of partial-onset seizures in epilepsy patients over 16 years of age.

Dr Iris Loew-Friedrich, chief medical officer and executive VP at UCB, commented: “Today is a major milestone for brivaracetam and an exciting day for everyone at UCB who is committed to its development.

“It is also an important time for the clinicians and patients whose involvement in brivaracetam clinical trials has been so important in helping up to address the need for new treatment options for adult patients who do not achieve partial-onset seizure control with current antiepileptic drugs.”

The filings are supported by data from three phase III studies, which evaluated the efficacy and safety of adjunctive brivaracetam in a 5-200mg daily dosage in patients with uncontrolled partial-onset seizures.

A fourth phase III study evaluated the safety and tolerability of adjunctive brivaracetam given to patients with the same symptoms.

The filing is a major milestone for UCB as it pursues its goal of building its epilepsy business following the loss of patent for Keppra in the US and EU in the past few years.

The company has since turned to other drugs in its epilepsy portfolio, including Vimpat (lacosamide). At the end of last year UCB announced a partnership with Daiichi Sankyo to bring Vimpat to Japan.

Article by
Kirstie Pickering

22nd January 2015

From: Sales



Featured jobs

Subscribe to our email news alerts


Add my company
M&F Health

M&F Health is a full service communications agency, dedicated to the health and wellbeing sector. We are an independent amongst...

Latest intelligence

The Biosimilar Challenge
How health behaviours and clinical outcomes are related
When HCPs understand patient activation levels they can actively guide patients towards more confident self-management of diverse health concerns....
The Periodic Table of Healthcare Communications
The definitive framework for building healthcare communication strategies and plans. Covering Brand Planning, Customer Experience and Multi-channel Marketing....